Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer

Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer

ABSTRACT Objective: To compare the prognosis estimated by standard prognostic criteria versus the prognosis estimated by the Oncotype DX. Methods: A retrospective study was performed on 22 patients with positive estrogen receptor, early-stage breast cancer who had an Oncotype DX recurrence score a...

Full description

Bibliographic Details
Main Authors:	Marcelo Roberto Pereira Freitas, Sergio Daniel Simon
Format:	Article
Language:	English
Published:	Instituto Israelita de Ensino e Pesquisa Albert Einstein 2011-09-01
Series:	Einstein (São Paulo)
Subjects:	Breast neoplasms/diagnosis Gene expression profiling
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082011000300354&tlng=pt

Similar Items

Clinical outcomes and Oncotype DX Breast Recurrence Score® in early‐stage BRCA‐associated hormone receptor‐positive breast cancer
by: Rachel M. Layman, et al.
Published: (2022-03-01)

Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer
by: Eoin P. Kerin, et al.
Published: (2022-12-01)

Prognostic Comparison between Oncotype DX<sup>®</sup> and a 23-Gene Classifier, RecurIndex<sup>®</sup>, on the Taiwan Breast Cancer Population
by: Chuan-Hsun Chang, et al.
Published: (2022-11-01)

Probability of a high recurrence score for breast cancer on the Oncotype DX test in males: a case series
by: Rafael Everton Assunção Ribeiro da Costa, et al.
Published: (2023-10-01)

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
by: Çağlar Ünal, et al.
Published: (2023-06-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
by: Berdunov V, et al.
Published: (2024-06-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
by: Daniel A. Goldstein, et al.
Published: (2020-07-01)

Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX
by: Ajay Basavanhally, et al.
Published: (2011-01-01)

Oncotype DX Recurrence Score in premenopausal women
by: Shiliang Zhang, et al.
Published: (2022-03-01)

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
by: John Loggie, et al.
Published: (2024-06-01)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
by: Aditya K. Sengupta, et al.
Published: (2020-11-01)

Oncotype Dx Results in Multiple Primary Breast Cancers
by: Michael J. Toole, et al.
Published: (2014-01-01)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
by: Yogeshkumar Malam, et al.
Published: (2022-08-01)

Utilization of Oncotype DX in an Inner City Population: Race or Place?
by: Amber A. Guth, et al.
Published: (2013-01-01)

Polymorphisms in Estrogen Receptor-Α and -Β Genes and Their Correlations with Risk Factors in Iranian Breast Cancer Patients
by: Abbasi, Sakineh
Published: (2009)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
by: Luca Licata, et al.
Published: (2023-06-01)

MiRNA expression deregulation correlates with the Oncotype DX® DCIS score
by: Olivier Loudig, et al.
Published: (2022-09-01)

A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol.
by: Matthew Northgraves, et al.
Published: (2024-01-01)

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
by: Zsuzsanna Varga, et al.
Published: (2013-01-01)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
by: Matthew G. Hanna, et al.
Published: (2017-01-01)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
by: Kathleen Iles, et al.
Published: (2022-03-01)

Correlation between MR Image-Based Radiomics Features and Risk Scores Associated with Gene Expression Profiles in Breast Cancer
by: Ga Ram Kim, et al.
Published: (2020-05-01)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
Published: (2013-01-01)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
by: Didi Feldman, et al.
Published: (2023-10-01)

A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions
by: Asma Munir, et al.
Published: (2023-01-01)

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx
by: Michał Jarząb, et al.
Published: (2024-10-01)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
by: Michael Crager, et al.
Published: (2022-11-01)

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
by: Stephane Thibodeau, et al.
Published: (2019-07-01)

MicroRNAs in breast cancer /
by: Lacroix, Marc, 1963-
Published: (2010)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
by: Richard Buus, et al.
Published: (2021-02-01)

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study
by: Arif Ali Awan, et al.
Published: (2024-02-01)

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
by: Nickolas Stabellini, et al.
Published: (2023-04-01)

Estrogen receptor status has no prognostic relevance in metaplastic breast carcinoma
by: Evi Abada, et al.
Published: (2022-01-01)

Estrogen receptor as the predictive factor for response to chemotherapy in breast cancer
by: Šušnjar Snežana, et al.
Published: (2006-01-01)

Prognostic validation and therapeutic decision‐making of the AJCC eighth pathological prognostic staging for T3N0 breast cancer after mastectomy
by: San‐Gang Wu, et al.
Published: (2020-03-01)

Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score<sup>®</sup> Test?
by: Francesca Galati, et al.
Published: (2022-11-01)

Correlation between the RNA Expression and the DNA Methylation of Estrogen Receptor Genes in Normal and Malignant Human Tissues
by: Ju Rong, et al.
Published: (2024-04-01)

MRI features of breast cancer immunophenotypes with a focus on luminal estrogen receptor low positive invasive carcinomas
by: Carla Chizuru Tajima, et al.
Published: (2024-08-01)